Chair, maybe you could ask Mr. Julian to grab a cup of coffee if he's struggling with his attention.
I apologize for directing it directly to Mr. Julian. It's much better to say it that way.
That said, what Mr. Julian was suggesting was that the good folks who provide medications to Canadians were not being truthful with their testimony that we heard. Of course, if we had more testimony, perhaps we could have heard opposing opinions, but we didn't, because of Mr. Julian and the costly coalition. We were able to hear only 10 hours of testimony. If he thinks that what they are saying is not true, then we'd be more than happy to hear more testimony. Just for clarity for Canadians, because of their motion on closure that limited the amount of testimony that could possibly be heard, we were very limited on who we were able to hear from.
Again, what we already have is an existing national bulk purchasing strategy under the auspices of the pan-Canadian Pharmaceutical Alliance. It really is beyond belief that what both Mr. Julian and Mr. Naqvi are saying, without transparency, is that they don't think that's a national bulk purchasing strategy. They think that perhaps in the future the Canadian drug agency will provide some of that, whereas this is in no way, shape or form limiting the ability to do it because we have already established that it is occurring now. The pharmacoeconomic discussion happened previously, before May 1, at CADTH, and is now.... I'm not entirely sure what's happening.
Mr. MacDonald, maybe you could make this clear to the committee.
Is there a joint CDA and CADTH, or is CADTH no longer relevant and just out of the picture altogether? Perhaps before I go on, you could make that clear to the committee. Is the governing structure now solely the Canadian drug agency and not CADTH, or is there some sort of overlap at the current time?
Ms. Boudreau, it looks like you might want to answer. If you do, please feel free.